Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
may 8th HVTN Full Group Meeting 2013
HVTN 098 Electroporation. Show and Tell. (4-5:30pm)
a planned trial to evaluate the safety and tolerability of pENNVaX®-Gp with plasmid IL-12,
given by intradermal or intramuscular injection with electroporation, in healthy HIV-1 uninfected adult volunteers.
Everywhereman- do you think Inovio finishes a big pharma partnership this year 2013..do you have any insight on how far along these talks are or which company we might be engaging with? would appreciate you thoughts on that
11th Vaccines Research & Development: All Things Considered Conference, to be held in Boston,
Day 3 - Wednesday, July 10, 2013
DNA & RNA Vaccines
8:10 Synthetic Vaccines for Difficult Targets
David Weiner, Professor, Department of Pathology and Laboratory Medicine; Chair, Gene Therapy and Vaccine Program, CAMB, University of Pennsylvania Perelman School of Medicine
DNA vaccines represent an important vaccine technology, which has many conceptual advantages over traditional vaccine platforms. However, in humans the immune potency of this approach has been poor. We have developed a combination of technologies for plasmid optimization, adjuvant technology which when combined with enhanced EP delivery results in dramatically improved immune potency of this platform in primates and humans. These combined DNA approaches drive immune response similar or superior to live viral vector protocols in important model systems including HIV, HPV therapy, Influenza among others. We will present data in animal models and in human studies that illuminate specific features of these improved DNA vaccine and benchmark their development against other important vaccine technologies. These studies have critical implications for the treatment or prevention of infection by difficult pathogens and in the expanding theater of immune therapy.
• New approaches to development of CTL in humans
• Details of the Synthetic DNA platform
• Novel Vaccine strategies for diverse pathogens
• Clinical performance in immune therapy setting
may 13-12 2013
Oncology Clinical Trials in Emerging Regions conference
PRESENTING FOR INOVIO
Mark Bagarazzi
Chief Medical Officer
Inovio Pharmaceuticals
HVTN 080 dNa; dNa + IL-12 dNa VGX (Inovio), profectus,
daIdS
env, gag, pol Together with HVTN 070 results, indicates electroporation with cytokine adjuvant increased
responses to dNa vaccination significantly.
I strongly suggest reading
http://hvtn.org/science/hvtnews/HVTNews-Feb2013.pdf
StockSavant I hear you man, some data from ino would be nice
Bagarazzi Mark 60,000 shares bought today
3 conferences all with in the next week starting Thursday
.57 wont stick ? where do you think it will open in the morn
2013 World Vaccine conference
Day 3 April 18th 2013
(DNA vaccine development landscape overview)
David Weiner Chairman scientific advisory board 9:10am
(The future of DNA vaccines)
Dr. Anthony Ford-Hutchinson Inovio scientific advisory board
9:40am
(Approaches to cancer immune therapy)
Dr Niranjan Y. Sardesai Inovio Pharmaceuticals
12.10pm
i got to it dont add that last . in the adress re-try it
i cant get to link
Finial phase 1 study data will once again show best in class immune responses for any current HIV vaccine Incase you don't know what that data means I just posted
The newsletter of the HIV Vaccine Trials Network April 5, 2013
(Tracey Day, Barbara Metch, Nicole Frahm, and Cecilia Morgan)
More recently, potential benefits of using adjuvants in conjunction with electroporation (EP) as a delivery method for DNA vaccines have been observed. EP involves delivery of short electrical pulses after DNA vaccine injection. These pulses serve to increase DNA uptake by cells. In HVTN 080, 3 vaccinations of PENNVAXTM-B (3 mg dose) delivered via EP elicited a 39% higher positive ICS response rate compared to 3 vaccinations of PENNVAXTM-B (6 mg dose) administered by standard intramuscular injection in HVTN 070. In addition, the use of adjuvants in conjunction with EP appears to be associated with further increase in vaccine potency. For example, in HVTN 080, 3 vaccinations of DNA with GENEVAXTM IL-12 delivered EP elicited a 61% higher positive ICS assay response rate compared to 3 standard intramuscular injections of the DNA vaccine alone (see Figure 2).9
Ongoing and planned HVTN studies will continue to investigate strategies to enhance vaccine potency via adjuvants or modes of administration. HVTN 087 is an ongoing study evaluating a DNA and vesicular stomatitis virus (VSV) vector prime/boost regimen in which the DNA will be co-administered with IL-12 and an EP device from another developer (see Table 1). A study currently in development, HVTN 098, will compare intramuscular administration of DNA via EP, with or without IL-12, with intradermal delivery via EP.
New cytokine adjuvants will also be investigated. For example, HVTN 094 is evaluating the cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF) co-expressed with HIV genes on a DNA plasmid. Future studies may also evaluate various adjuvants with proteins for their ability to enhance immunogenicity and increase response durability of protein immunogens.
Tracey Day is HVTN Senior Science Writer, Barbara Metch is Senior Statistical Analyst working with the HVTN, Nicole Frahm is Associate Director, Laboratory Sciences at the HVTN Laboratory Program, Cecilia Morgan is HVTN Associate Director, Scientific Development.
industrial hemp bill passes Colorado Senate committee
The Denver Post 4/10/2013
A Map That Shows the Dramatic Spread of Legal Weed in the U.S
Apr 8, 2013
Looking at the recent spread of liberalized marijuana laws across the United States, it's hard not to think we're entering some kind of Weed Spring. The latest state to act is Maryland, where on Monday the state senate approved a bill legalizing medical marijuana by 42 to 4, sending it to Gov. Martin O'Malley, who is expected to sign it into law. Several state legislatures are considering relaxing their restrictions on marijuana. A majority of Americans now favor legalizing marijuana, and 65 percent of young people support legalizing it, suggesting support will grow. The Justice Department still won't say how it will deal with marijuana legalization in Colorado and Washington -- it's still banned by the federal government -- but officials in both states say they're going ahead. "We intend to move forward with supporting the will of the people," Washington Attorney General Bob Ferguson told Talking Points Memo.
That's doesn't mean there haven't been setbacks for the pro-weed crowd in recent years. California voters rejected a legalization initiative in 2010, and Oregon voters did the same in 2012. Bills to legalize weed have died in Hawaii and New Hampshire this year. But as our map GIF above shows, the trajectory is unmistakably toward legalization. Here are four state legislatures debating whether to follow Maryland in 2013:
Oregon. The state House is considering a bill that would legalize, regulate, and tax marijuana, USA Today reported last week. House Speaker Tina Kotek says passing the bill this session would be a "heavy lift." Voters rejected a ballot initiative to legalize it last fall.
Maine. Medical marijuana is so well-established in Maine that workers at a major pot dispensary protested last week because they said owners were blocking their efforts to unionize. A bill to legalize marijuana has 35 co-sponsors. "There's a momentum building and it's clear it's coming to the Northeast and to Maine," state Rep. Diane Russell, who introduced the bill, said Sunday. "I would rather see us get ahead of the curve and be ready. The train is coming and if we bury our heads in the sand, we're going to get hit."
Illinois. The state House is working on a medical marijuana bill that would allow patients with certain diseases -- like cancer, HIV/ AIDS, and multiple sclerosis -- to use the drug if their doctor prescribed it and the Department of Health approved. Last week, two state representatives wrote an op-ed saying Illinois' bill "can serve as a national model."
Vermont. A state House judiciary committee held hearings last week on a marijuana decriminalization bill. Originally supporters wanted to decriminalize possession of 2 ounces, but that has been lowered to 1 ounce. The bill is expected to be voted out of committee next week.
Elsewhere: Alabama rejected medical marijuana in February, but in April, a state legislator introduced a bill to legalize 1 ounce for recreational use. Several states have pending medical marijuana legislation. Kentucky's legalization of hemp will become law.
New Hampshire Senate to Hold Marijuana Decriminalization Hearings Thursday April 9, 2013
CONCORD, NH — House Bill 621, which seeks to make minor marijuana offenses — possession of up to one-quarter of one ounce — a fine-only, non-criminal infraction, has been scheduled for a hearing before the Senate Judiciary Committee on Thursday, April 11.
The hearings begin at 9:00 am on April 11, in Room 100 of the State House in Concord. Later in the day, at 1:00 pm, testimony on a bill that would allow the medical use of marijuana in New Hampshire will be heard by the Senate Committee on Health, Education & Human Services.
Last month, House members voted 214 to 115 in favor of an amended version of House Bill 621.
Under the amended version of the bill, possession of under a quarter ounce of marijuana will result in a fine of up to$200. The original version of the bill would have decriminalized up to one ounce of marijuana with a fine of up to $100.
Under present law, the possession of any amount of cannabis is classified as a criminal misdemeanor publishable by up to one-year in jail and a $2,000 fine. This proposal seeks to make the possession up to one-quarter of one ounce a fine-only, non-criminal infraction.
The vote marks the fourth time in five years that House lawmakers have approved decriminalizing cannabis. More than 50 additional House lawmakers approved the measure this year as opposed to last year.
Nevertheless, this measure is anticipated to face resistance in the Senate as well as from Gov. Maggie Hassan. Please take time today to contact your member of the Senate and urge them to consider HB 621.
You may also wish to contact Gov. Hassan and let her know that HB 621 is a fiscally sensible proposal that will better enable municipal police, prosecutors, and the courts to reallocate their existing resources toward activities that will better serve the public.
New Hampshire residents can contact your state Senator today and urge him or her to support HB 621
Maine Legislative Committee Strongly Endorses Hemp Cultivation Bill
04/09/2013 Reported By: Susan Sharon
legislative committee has given strong support to a bill that would legalize industrial hemp production in Maine. By a vote of nine-to-one, the Agriculture, Conservation and Forestry Committee has endorsed the idea of loosening restrictions on hemp cultivation, which is currently grown in Maine only for experimental purposes. Susan Sharon reports.
Supporters of the bill say its only intent is to allow Maine farmers to diversify their crops. Hemp can be used to make paper, rope, clothes and fuel oil. But historically, hemp production has been so closely associated with its cousin, cannabis, that some believe it has simply become another victim of the war on drugs.
While the Canadian government has authorized an industrial hemp program for about 15 years, U.S. prohibitions prevent farmers from growing it because it is still considered a Schedule 1 drug. That's starting to change. Legislation is pending at the federal level to relax the rules for hemp, and Kentucky has just authorized its use.
But Paul McCarrier, a Maine lobbyist with the Medical Marijuana Caregivers Association, told committee members that there are still licensing safeguards in the Kentucky legislation that are similar to Maine's.
"This is a very small step. I believe it's the same thing, where it has to be approved by the Department of Agriculture's Commissioner, but if the commissioner decides that the person or the entity is trustworthy enough, is reputable enough, to grow industrial hemp than they'd be able to allow those licenses to be there," McCarrier said.
Maine's bill would do away with a provision that requires applicants for an industrial hemp license to submit fingerprints to the state, and with a another that requires federal approval for licenses to grow it. The bill, as amended, would also ensure that hemp seeds come from Canadian-approved distributors that restrict THC, the active ingredient in marijuana.
Only one committee member voted against the bill, which now heads to the House and Senate for further consideration and votes.
Industrial hemp production one step closer in Kentucky Apr. 9, 2013
Agriculture Commissioner James Comer credited industrial hemp supporters for encouraging lawmakers and Gov. Steve Beshear to approve historic legislation that will help restore hemp production to Kentucky.
Gov. Beshear said he will take no action on Senate Bill 50, allowing it to become law.
“This shows what can happen when the people get behind positive legislation that has the potential to create jobs and opportunity for Kentucky,” Comer said.
“Six months ago, industrial hemp was on nobody’s radar. Now, SB 50 will become the law of the Commonwealth. I’m grateful to all the people — legislators, farmers, business people, Republicans, Democrats — who made their voices heard on this issue, and to Sen. Paul Hornback for taking a chance and sponsoring the bill.”
Commissioner Comer plans to call on Washington and work with Kentucky’s congressional delegation to ask federal authorities for permission to grow industrial hemp in Kentucky.
“Now that this bill will become law, the federal government will know that Kentucky’s leaders from both parties are united in our intent to bring industrial hemp production back to the Commonwealth in a responsible way,” Commissioner Comer said.
Senate Bill 50 passed in the Kentucky General Assembly in the final hour of the recently concluded legislative session after months of debate and expert testimony.
Senate Bill 50 creates an administrative framework, to be managed by the Kentucky Department of Agriculture, for industrial hemp production in Kentucky.
The legislation calls for hemp demonstration projects by the University of Kentucky and other public universities that choose to participate.
Under the bill, the Kentucky State Police are required to conduct background checks on applicants for licenses to grow industrial hemp.
Niranjan is still scheduled to present at the World Vaccines Conference next Thursday, April 18th.
Checking on times.
The presentation will not be webcast.
Bernie Hertel
Senior Director, Corporate Communications
858 336 5579
bhertel@inovio.com
Inovio Pharmaceuticals Inc.
NYSE MKT: INO
how is l2 looking? can we break out of this current lid at .5
L2..how is it looking?
what is your guys opinion on why there is so much volume today
what did you buy in at?
my honest advice, if you can gain a nice piece of profit in a really low penny stock on the otc market take it..buying at these levels though and holding for a bit could serve you well considering redg pps is at all time low but i only like that theory if u can buy at dirt cheap lows like anyone who bought today, im in at .02 rolled the dice now im in the red i have patience though and will sit on my shares here for a few months and see what happens
check day three of the conference April 18th you'll notice when you scroll over these time slots it shows who's presenting, at 12:10 you find a section labeled Approaches to cancer immune therapy nothing shows for who's presenting..well the person who is presenting is Dr. Niranjan Y. Sardesai Chief Operating Officer at INOVIO PHARMACEUTICALS...its a long story as to why i know this but thats what it is
ill see if i can find link
Ino will be presenting at world vaccine conference
how can we confirm that
Paulness is that the number 1 mill shorted..i hope so, i hope some fools added to their short positions today to
your right Inovio did a really good job shaking off this ctec data only 5 cent drop ill take that for sure..im ready to see our syncon and new generation delivery devices in action
hopefully Bernies sheds some clarity on that to unknowing investors
i expect somewhat of a reaction but your right its not inos vaccine at all i was hoping to read how electroporation fared in the study
not much of a response
Unless we should release anything to the contrary.
Best regards,
Anders Vahlne
From: Kyle Ramer <kyle.ramer@yahoo.com>
Reply-To: Kyle Ramer <kyle.ramer@yahoo.com>
Date: Thursday, March 28, 2013 8:22 AM
To: Anders Vahlne <anders.vahlne@ki.se>
Subject: 1st qtr Chronvac-c Results
Hello, My name is Kyle Ramer I am an american shareholder with your company with a modest position of shares. My question is does Chrontech still stand by their 1st qtr chronvac phase 2 results deadline?
Thank you
thanks for the info I wasnt aware of that good stuff though
chrontechs exchange is closed Friday and i believe today's trading day is shortened
Unless we should release anything to the contrary.
Best regards,
Anders Vahlne
From: Kyle Ramer <kyle.ramer@yahoo.com>
Reply-To: Kyle Ramer <kyle.ramer@yahoo.com>
Date: Thursday, March 28, 2013 8:22 AM
To: Anders Vahlne <anders.vahlne@ki.se>
Subject: 1st qtr Chronvac-c Results
Hello, My name is Kyle Ramer I am an american shareholder with your company with a modest position of shares. My question is does Chrontech still stand by their 1st qtr chronvac phase 2 results deadline?
Thank you
Journal proves ino's aprroach to treatment and vaccination look at the big pharma company's with a stake in this research...the future of vaccines seems to be headed towards DNA vaccines. Look up the paper released through plos titled Multivalent Human papillaomavirus DNA vaccination utilizing electroporation